Tirzepatide has significantly lower constipation rates and may improve bowel function
Intravenous glutathione for skin lightening: inadequate safety data
Cardiovasc Diabetol 21:169
The shortage status had been a critical factor enabling compounding facilities to legally produce tirzepatide, which is otherwise protected by patents
10.1152/physrev.00014.2015 176
The medication works by: Enhancing insulin secretion in a glucose-dependent manner, reducing the risk of hypoglycemia Suppressing glucagon release when blood glucose levels are elevated Slowing gastric emptying , which prolongs satiety and reduces appetite Acting on central appetite regulation in the hypothalamus to decrease food intake Zepbound is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and gradually titrated upward (5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum of 15 mg) based on individual tolerance and therapeutic response